What’s in a name: the potential impact of the updated terminology of polyendocrine metabolic ovarian syndrome (PMOS)

INTRODUCTION: Polycystic ovary syndrome (PCOS) was recently renamed polyendocrine metabolic ovarian syndrome (PMOS). AREAS COVERED: We review the renaming process, the potential advantages, and the challenges associated with this global effort. A large consortium of experts and patient representatives debated whether renaming was justified, what principles should guide a new name, and how such a change could be implemented without disrupting clinical care, research, education, or patient communication. Surveys indicated that awareness of the broader features of the syndrome improved in the last years after dissemination strategies and patient advocacy initiatives, but important gaps remained, particularly around the risk of comorbidities. EXPERT OPINION: New perspectives emerge with renaming PCOS into PMOS after a carefully planned effort to improve scientific accuracy, patient understanding, and clinical communication while minimizing confusion during implementation. The new terminology emphasizes the syndrome's endocrine and metabolic nature and removes the misleading reference to 'polycystic' ovaries. Similar to previous successful nomenclature updates in gynecology, this gradual transition aims to enhance education, interdisciplinary care, research, and long-term management, ultimately supporting more accurate diagnosis and improved patient outcomes.